Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

6 Sökresultat.
Relevans Bedömning Nya först Gamla först

Investigational Product – IV Dosing Day 1 Post- Infection Mepolizumab HES NCT00086658 - Investigational Product – IV Dosing Day 1 Post- Infection

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 6 Dataelement, 1 Språk
Item-grupp: Investigational Product Dose Intravenous
Study part: Investigational Product – IV Dosing Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pharmacokinetics- Blood Day 1 Post- Infection Mepolizumab HES NCT00086658 - Pharmacokinetics- Blood Day 1 Post- Infection

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: Pharmacokinetics Blood
Study part: Pharmacokinetics- Blood Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Central Laboratory –Blood Day 1 Post- Infection Mepolizumab HES NCT00086658 - Central Laboratory –Blood Day 1 Post- Infection

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 2 Dataelement, 1 Språk
Item-grupp: Central laboratory
Study part: Central Laboratory –Blood Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Randomisation Number Day 1 Post- Infection Mepolizumab HES NCT00086658 - Randomisation Number Day 1 Post- Infection

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: Randomisation Number
Study part: Randomisation Number Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Concomitant Medications Day 1 Post- Infection Mepolizumab HES NCT00086658 - Concomitant Medications Day 1 Post- Infection

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Concomitant Medications
Study part: Concomitant Medications Day 1 Post- Infection .A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Adverse Events Day 1 Post- Infection Mepolizumab HES NCT00086658 - Adverse Events Day 1 Post- Infection

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Adverse Events
Study part: Adverse Events Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial